{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:48:05Z","timestamp":1769528885669,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"ImPaCCT Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00280-022-04482-8","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T10:02:39Z","timestamp":1666000959000},"page":"445-453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL)"],"prefix":"10.1007","volume":"90","author":[{"given":"Suja","family":"Johnson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chetan","family":"Dhamne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hari","family":"Sankaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khushboo A.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pallavi","family":"Rane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmaly Roy","family":"Moulik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shraddha Mahesh","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murari","family":"Gurjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav","family":"Narula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shripad","family":"Banavali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8942-0332","authenticated-orcid":false,"given":"Vikram","family":"Gota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"4482_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/0976-500X.184769","volume":"7","author":"RA Egler","year":"2016","unstructured":"Egler RA, Ahuja SP, Matloub Y (2016) L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother 7:62\u201371. https:\/\/doi.org\/10.4103\/0976-500X.184769","journal-title":"J Pharmacol Pharmacother"},{"key":"4482_CR2","first-page":"241","volume":"1","author":"VI Avramis","year":"2006","unstructured":"Avramis VI, Tiwari PN (2006) Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine 1:241","journal-title":"Int J Nanomedicine"},{"key":"4482_CR3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","volume":"44","author":"VI Avramis","year":"2005","unstructured":"Avramis VI, Panosyan EH (2005) Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 44:367\u2013393. https:\/\/doi.org\/10.2165\/00003088-200544040-00003","journal-title":"Clin Pharmacokinet"},{"key":"4482_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/S10495-018-1506-3\/FIGURES\/7","volume":"24","author":"LE M\u00e9tayer","year":"2019","unstructured":"M\u00e9tayer LE, Brown RD, Carlebur S et al (2019) Mechanisms of cell death induced by arginase and asparaginase in precursor B-cell lymphoblasts. Apoptosis 24:145\u2013156. https:\/\/doi.org\/10.1007\/S10495-018-1506-3\/FIGURES\/7","journal-title":"Apoptosis"},{"key":"4482_CR5","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1021\/ACS.BIOCHEM.0C00354","volume":"59","author":"A Radadiya","year":"2020","unstructured":"Radadiya A, Zhu W, Coricello A et al (2020) Improving the treatment of acute lymphoblastic leukemia. Biochemistry 59:3193\u20133200. https:\/\/doi.org\/10.1021\/ACS.BIOCHEM.0C00354","journal-title":"Biochemistry"},{"key":"4482_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/CNCR.25489","volume":"117","author":"R Pieters","year":"2011","unstructured":"Pieters R, Hunger SP, Boos J et al (2011) L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 117:238\u2013249. https:\/\/doi.org\/10.1002\/CNCR.25489","journal-title":"Cancer"},{"key":"4482_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/ANNONC\/MDT323","volume":"24","author":"GL Lopes","year":"2013","unstructured":"Lopes GL (2013) Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India. Ann Oncol Off J Eur Soc Med Oncol 24:13\u201316. https:\/\/doi.org\/10.1093\/ANNONC\/MDT323","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"4482_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4103\/2249-4863.161305","volume":"4","author":"P Mathew","year":"2015","unstructured":"Mathew P (2015) Generic drugs: review and experiences from South India. J Fam Med Prim Care 4:319. https:\/\/doi.org\/10.4103\/2249-4863.161305","journal-title":"J Fam Med Prim Care"},{"key":"4482_CR9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/J.JVAL.2012.04.004","volume":"15","author":"A Cameron","year":"2012","unstructured":"Cameron A, Mantel-Teeuwisse AK, Leufkens HGM, Laing RO (2012) Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health 15:664\u2013673. https:\/\/doi.org\/10.1016\/J.JVAL.2012.04.004","journal-title":"Value Health"},{"key":"4482_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0140-6736(08)61762-6","volume":"373","author":"A Cameron","year":"2009","unstructured":"Cameron A, Ewen M, Ross-Degnan D et al (2009) Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet (London, England) 373:240\u2013249. https:\/\/doi.org\/10.1016\/S0140-6736(08)61762-6","journal-title":"Lancet (London, England)"},{"key":"4482_CR11","unstructured":"Sallan SE, Hitchcock-Bryan S, Gelber R, et al (1983) Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia - PubMed. In: Cancer Res. https:\/\/pubmed.ncbi.nlm.nih.gov\/6352020\/. Accessed 28 Jun 2022"},{"key":"4482_CR12","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1056\/NEJMOA0900386","volume":"360","author":"C-H Pui","year":"2009","unstructured":"Pui C-H, Campana D, Pei D et al (2009) Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360:2730\u20132741. https:\/\/doi.org\/10.1056\/NEJMOA0900386","journal-title":"N Engl J Med"},{"key":"4482_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/LEU.2009.257","volume":"24","author":"A M\u00f6ricke","year":"2010","unstructured":"M\u00f6ricke A, Zimmermann M, Reiter A et al (2010) Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24:265\u2013284. https:\/\/doi.org\/10.1038\/LEU.2009.257","journal-title":"Leukemia"},{"key":"4482_CR14","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/CCO.0000000000000125","volume":"26","author":"MR Abboud","year":"2014","unstructured":"Abboud MR, Ghanem K, Muwakkit S (2014) Acute lymphoblastic leukemia in low and middle-income countries: disease characteristics and treatment results. Curr Opin Oncol 26:650\u2013655. https:\/\/doi.org\/10.1097\/CCO.0000000000000125","journal-title":"Curr Opin Oncol"},{"key":"4482_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4103\/2278-330X.187591","volume":"5","author":"RS Arora","year":"2016","unstructured":"Arora RS, Arora B (2016) Acute leukemia in children: a review of the current Indian data. South Asian J Cancer 5:155. https:\/\/doi.org\/10.4103\/2278-330X.187591","journal-title":"South Asian J Cancer"},{"key":"4482_CR16","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/BCP.14216","volume":"86","author":"H Sankaran","year":"2020","unstructured":"Sankaran H, Sengupta S, Purohit V et al (2020) A comparison of asparaginase activity in generic formulations of E.coli derived L-asparaginase: in-vitro study and retrospective analysis of asparaginase monitoring in pediatric patients with leukemia. Br J Clin Pharmacol 86:1081\u20131088. https:\/\/doi.org\/10.1111\/BCP.14216","journal-title":"Br J Clin Pharmacol"},{"key":"4482_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/PBC.29046","author":"J Sidhu","year":"2021","unstructured":"Sidhu J, Gogoi MP, Agarwal P et al (2021) Unsatisfactory quality of E. coli asparaginase biogenerics in India Implications for clinical outcomes in acute lymphoblastic leukaemia. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/PBC.29046","journal-title":"Pediatr Blood Cancer"},{"key":"4482_CR18","doi-asserted-by":"publisher","unstructured":"Narula G, Arora B, Subramanian PG, et al. (2017) Outcome of B-ALL treated with a risk-stratified and response-adapted protocol: interim analysis of a single-institution pilot study for a multicenter collaborative protocol from India. the 49th congress of the international society of paediatric oncology (SIOP) Washington, DC, USA October 12\u201315, 2017. Pediatr Blood Cancer 64 Suppl 3: https:\/\/doi.org\/10.1002\/PBC.26772","DOI":"10.1002\/PBC.26772"},{"key":"4482_CR19","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","volume":"32A","author":"J Boos","year":"1996","unstructured":"Boos J, Werber G, Ahlke E et al (1996) Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 32A:1544\u20131550. https:\/\/doi.org\/10.1016\/0959-8049(96)00131-1","journal-title":"Eur J Cancer"},{"key":"4482_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1023\/A:1008368916800","volume":"11","author":"C Rizzari","year":"2000","unstructured":"Rizzari C, Zucchetti M, Conter V et al (2000) L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol Off J Eur Soc Med Oncol 11:189\u2013193. https:\/\/doi.org\/10.1023\/A:1008368916800","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"4482_CR21","unstructured":"Riccardi R, Holcenberg JS, Glaubiger DL, et al (1981) L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans - PubMed. In: Cancer Res. 41(11 Pt 1). https:\/\/pubmed.ncbi.nlm.nih.gov\/6895481\/. Accessed 28 Jun 2022"},{"key":"4482_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/S00280-003-0734-5","volume":"53","author":"M Tsurusawa","year":"2004","unstructured":"Tsurusawa M, Chin M, Iwai A et al (2004) L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment. Cancer Chemother Pharmacol 53:204\u2013208. https:\/\/doi.org\/10.1007\/S00280-003-0734-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"4482_CR23","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","volume":"33","author":"CH Pui","year":"2015","unstructured":"Pui CH, Yang JJ, Hunger SP et al (2015) Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol 33:2938\u20132948. https:\/\/doi.org\/10.1200\/JCO.2014.59.1636","journal-title":"J Clin Oncol"},{"key":"4482_CR24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.4103\/0019-509X.146723","volume":"51","author":"VS Gota","year":"2014","unstructured":"Gota VS, Patial P (2014) Toward better quality of anticancer generics in India. Indian J Cancer 51:366\u2013368. https:\/\/doi.org\/10.4103\/0019-509X.146723","journal-title":"Indian J Cancer"},{"key":"4482_CR25","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1080\/10428194.2018.1542146","volume":"60","author":"RJ Schore","year":"2019","unstructured":"Schore RJ, Devidas M, Bleyer A et al (2019) Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on children\u2019s oncology group AALL07P4. Leuk Lymphoma 60:1740\u20131748. https:\/\/doi.org\/10.1080\/10428194.2018.1542146","journal-title":"Leuk Lymphoma"},{"key":"4482_CR26","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.3324\/HAEMATOL.2018.206433","volume":"104","author":"C Rizzari","year":"2019","unstructured":"Rizzari C, Lanvers-Kaminsky C, Valsecchi MG et al (2019) Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. Haematologica 104:1812. https:\/\/doi.org\/10.3324\/HAEMATOL.2018.206433","journal-title":"Haematologica"},{"key":"4482_CR27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/J.EBIOM.2018.03.005","volume":"30","author":"PP Zenatti","year":"2018","unstructured":"Zenatti PP, Migita NA, Cury NM et al (2018) low bioavailability and high immunogenicity of a new brand of E. colil-asparaginase with active host contaminating proteins. EBioMedicine 30:158\u2013166. https:\/\/doi.org\/10.1016\/J.EBIOM.2018.03.005","journal-title":"EBioMedicine"},{"key":"4482_CR28","unstructured":"Earl M. (2009) Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia - PubMed. In: Clin Adv Hematol Oncol HO, 7(9). https:\/\/pubmed.ncbi.nlm.nih.gov\/20020672\/. Accessed 28 Jun 2022"},{"key":"4482_CR29","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3109\/10428194.2015.1101098","volume":"57","author":"N Hijiya","year":"2016","unstructured":"Hijiya N, Van Der Sluis IM (2016) Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma 57:748\u2013757. https:\/\/doi.org\/10.3109\/10428194.2015.1101098","journal-title":"Leuk Lymphoma"},{"key":"4482_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.5731\/PDAJPST.2012.00886","volume":"66","author":"A Rathore","year":"2012","unstructured":"Rathore A (2012) Guidelines on similar biologics: regulatory requirements for marketing authorization in India. PDA J Pharm Sci Technol 66:393. https:\/\/doi.org\/10.5731\/PDAJPST.2012.00886","journal-title":"PDA J Pharm Sci Technol"},{"key":"4482_CR31","unstructured":"GUIDELINES ON SIMILAR BIOLOGICS: Regulatory requirements for marketing authorization in india (2016)"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04482-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04482-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04482-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T10:09:12Z","timestamp":1667642952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04482-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4482"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04482-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,17]]},"assertion":[{"value":"16 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Ethics Committee of Tata Memorial Hospital. All trial participants provided written informed consent prior to their enrolment. The study was carried out in accordance with the Declaration of Helsinki and International Conference on Harmonization\u2014Good Clinical Practice (ICH\u2010GCP) guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}